Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
146 hedge funds and large institutions have $717M invested in Synergy Pharmaceuticals, Inc Common Stock in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 67 increasing their positions, 27 reducing their positions, and 38 closing their positions.
148% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 27
1% more capital invested
Capital invested by funds: $708M → $717M (+$8.92M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 164 → 146 (-18)
12% less call options, than puts
Call options by funds: $7.57M | Put options by funds: $8.63M
42% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
+$17.1M |
| 2 |
BlackRock
New York
|
+$8.87M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.75M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$5.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$5.21M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.56M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.13M |
| 4 |
GL
Governors Lane
New York
|
-$4.05M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$2.97M |
SGYP Hedge Fund Activity: Q2 2017 in Review
146 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q2 2017, worth a combined $717M — up 1.3% from $708M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of SGYP and 22 opened new positions — a net loss of 16 holders — while 27 trimmed existing stakes and 67 added.
The largest buyer was Tourbillon Capital Partners, opening a new position worth an estimated $17.1M. The largest seller was Kingdon Capital Management, cutting an estimated $5.21M.
- 146 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q2 2017, down from 164 in Q1 2017.
- Funds reported $717M of Synergy Pharmaceuticals, Inc Common Stock stock for Q2 2017, up 1.3% quarter-over-quarter.
- 22 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q2 2017 and 38 closed out, a net change of -16 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q2 2017 was Tourbillon Capital Partners, an estimated $17.1M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q2 2017 was Kingdon Capital Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q2 2017.